US FDA three lines addition to consent documents cost $3 per trial participant
This article was originally published in Scrip
When US Congress passed the Drug Administration Amendments Act of 2007 (FDAAA) that, amongst other measures, introduced the publicly accessible database of clinical trials (www.ClinicalTrials.gov), it may not have realised how complicated it would be to introduce wording into informed consent document telling trial subjects that results of their trials would be included on that website.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.